SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-008768
Filing Date
2021-01-28
Accepted
2021-01-28 16:05:50
Documents
14
Period of Report
2021-01-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm214205d3_8k.htm   iXBRL 8-K 31910
2 EXHIBIT 5.1 tm214205d3_ex5-1.htm EX-5.1 15968
3 EXHIBIT 10.1 tm214205d3_ex10-1.htm EX-10.1 195228
  Complete submission text file 0001104659-21-008768.txt   472852

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vyne-20210126.xsd EX-101.SCH 3214
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20210126_lab.xml EX-101.LAB 34592
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20210126_pre.xml EX-101.PRE 22729
7 EXTRACTED XBRL INSTANCE DOCUMENT tm214205d3_8k_htm.xml XML 3712
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 21564988
SIC: 2834 Pharmaceutical Preparations